Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 3/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 10/20 | 0.42 |
| ▸ | LCLAT1 | Q6UWP7 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 4/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.36 |
| ▸ | MERTK | Q12866 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24464270 | 0.92 | UGCG (0.62) | UGCGSCN9AMETLCLAT1AXL | |
| SCHEMBL29907412 | 0.92 | UGCG (0.62) | UGCGSCN9AMETLCLAT1AXL | |
| SCHEMBL29907614 | 0.92 | UGCG (0.53) | UGCGSCN9AMETLCLAT1 | |
| SCHEMBL29907352 | 0.88 | UGCG (0.67) | UGCGSCN9AMETLCLAT1AXL | |
| SCHEMBL29907363 | 0.87 | SCN9A (0.46) | UGCGSCN9ALCLAT1MEN1HTT | |
| SCHEMBL29907369 | 0.86 | UGCG (0.62) | UGCGSCN9AMETLCLAT1ALDH1A1 | |
| SCHEMBL29907392 | 0.82 | UGCG (0.79) | UGCGMETLCLAT1AXLTYRO3 | |
| SCHEMBL29907421 | 0.81 | UGCG (0.78) | UGCGSCN9AMETLCLAT1AXL | |
| SCHEMBL29907661 | 0.80 | UGCG (0.47) | UGCGSCN9AMETLCLAT1KMT2A | |
| SCHEMBL29907372 | 0.80 | UGCG (0.63) | UGCGSCN9AMETAXLTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885SCN9A 1952/4885MET 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.